Biomoti Limited

Overview

Browse spinouts

Legal name

BIOMOTI LIMITED

Region

West Midlands

Registered address

Unknown

Insolvency history

No

Company events

Reference milestones and recent Companies House filing stream events.

3 events

29 Oct

2024

Gazette Notice Voluntary

Gazette

GAZ1(A) | Transaction MzQ0MDI2Njk5N2FkaXF6a2N4 | Paper/PDF filed

Published 25 Oct 2024 01:12

21 Oct

2024

Dissolution Application Strike Off Company

Dissolution

DS01 | Transaction MzQ0MDIzOTM0MWFkaXF6a2N4

Published 21 Oct 2024 08:46

06 Jun

2009

Incorporated

Inception

Company registered at Companies House

Spinout profile

3 entries

Company description

Biomoti was created to develop our drug delivery platform, initially building a lead candidate for the treatment of ovarian cancer, Oncojan.

BioMoti develops immunotherapeutic microparticles whose role is to enter cancer cells and release drugs within it.

Project impact

BioMoti had a succesful first seed funding round, was shortlisted in the Best Emerging Biotech category (Sponsored by James Cowper) alongside Atopix Therapeutics and Autifony Therapeutics for the OBN Awards 2013, and has won an MRC studentship award with QMUL.

Biomoti

2009

http://www.biomoti.com

BioMoti

2009

http://www.biomoti.com

BioMoti

2009

http://www.biomoti.com

Public funding

3 awards

First funded

2013

Funded years

2013, 2017, 2018

Age at first award

3 years

Projects

2018 Feasibility Studies Lead participant

Paclitaxel-loaded biodegradable microparticle production optimised on a microfluidics platform

1 Mar 2018 to 28 Feb 2019

Awarded

£14,773

Total cost £21,104

"Cancer is the second leading cause of global mortality with over 8,000,000 deaths worldwide (WHO, 2015) and 163,444 in the UK (CRUK, 2014). There continues to be large unmet clinical need for patients with certain cancers such as ovarian where median survival is only 3 years. These survival rates have not changed for the past 3 decades. BioMoti, in a new...

2017 Collaborative R&D Lead participant

Immunomodulation and sustained treatment of CD95L stratified tumours by precision targeting

1 Aug 2017 to 31 Oct 2019

Awarded

£132,514

Total cost £189,305

Cancer is the second leading cause of global mortality with over 8,000,000 deaths worldwide (WHO, 2015) and 163,444 in the UK (CRUK, 2014). Interventions that leverage the immune system, including antibodies and cell-based therapies, promise to revolutionise cancer treatment with cures seen in previously untreatable patients. However, many obstacles remai...

2013 Feasibility Studies Lead participant

MOTI1001: Oncojan based drug candidate for the treatment of ovarian cancer

1 Apr 2013 to 31 Mar 2014

Awarded

£150,000

Total cost £202,570

One in three of us will get cancer and increases in life expectancy indices will only exacerbate this statistic. Unfortunately, many cancer subtypes have very poor survival rates. Most chemotherapeutics have devastating side effects such as hair loss, nausea, weakened immunity and fatigue. BioMoti is developing an exciting technology platform based on Que...

Product types

Collaborative R&D Feasibility Studies